K-80003
Code | Size | Price |
---|
TAR-T11734-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T11734-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
K-80003 is a potent inhibitor of cancer cell growth and tRXRα-dependent Akt activation.
CAS:
1292821-90-9
Formula:
C22H21FO2
Molecular Weight:
336.406
Pathway:
Tyrosine Kinase/Adaptors
Purity:
0.98
SMILES:
CC(C)c1ccc(C=C2C(C)=C(CC(O)=O)c3cc(F)ccc23)cc1
Target:
c-Fms
References
1. Zhou H, et al. NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell. 2010 Jun 15;17(6):560-73.
2. Chen L, et al. Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXR?. Nat Commun. 2017 Jul 17;8:16066.